Vol. 4 No. 3 (2016): December 2016

Published: 2016-12-31

Editorial

PARP inhibitors in ovarian cancer treatment: more than a hope

Angela Musella, Claudia Marchetti, Pierluigi Benedetti Panici

3-5
- PDF

Review

Sequential medical therapy in renal carcinoma

Raffaele Ratta, Aristotelis Bamias

6-11
- PDF

Pro & Cons editorial

Timing of medical therapy and surgery in liver metastatic colorectal cancer

Gianluca Masi, Alessandro Ferrero, Donatella Marino

12-19
- PDF

Breaking from the Lab

Molecular profile in breast cancer

Francesco Pantano, Loretta D’Onofrio, Aleix Prat

20-24
- PDF

Clinical original article

Evaluation of capecitabine in patients with platinum-pretreated advanced or recurrent cervical carcinoma: a retrospective study of the IRCCS National Cancer Institute of Milan

Stefano Lepori, Caterina Fontanella, Giuseppa Maltese, Domenica Lorusso

25-29
- PDF
Managing pazopanib toxicity in the treatment of advanced soft tissue sarcoma

Paola Boccone, Letizia Laera, Giacomo Giulio Baldi, Sara Miano, Sandra Aliberti, Francesco Tolomeo, Lorenzo D’Ambrosio, Giovanni Grignani

30-35
- PDF

Meet the expert

Case 1 – Multidisciplinary treatment of a giant cell tumor of the bone affecting the sacrum of a young woman

Lorenzo D’Ambrosio, Paola Boccone, Pietro Pellegrino, Sara Miano, Ilaria Bertotto, Antonio Manca, Alberto Pisacane, Giovanni Grignani, Raimondo Piana, Piotr Rutkowski

36-41
- PDF
Case 2 – Lack of response to trastuzumab in a patient with metastatic gastric cancer progressing after extended response to MET inhibitor therapy

Elena Mori, Giacomo Giulio Baldi, Marco Scatizzi, Antonio Castagnoli, Lavinia Pugliese, Giuseppe Di Fiore, Rossana Fargnoli, Letizia Laera, Samantha Di Donato, Bruno Daniele

42-46
- PDF

Methodological corner

How to assess response to immune therapy

Judith Michels, Emilie Lanoy, Caroline Caramella, Christian Marth

47-51
- PDF

Letter to the Editor

Letter to the Editor

Francesco Perrone

52
- PDF